1
|
Anderson BO and Jakesz R: Breast cancer
issues in developing countries: An overview of the Breast Health
Global Initiative. World J Surg. 32:2578–2585. 2008. View Article : Google Scholar : PubMed/NCBI
|
2
|
Annual Reports of the Department of
Health, the Executive Yuan, Republic of China (Taiwan), 2005
|
3
|
Leong SP, Shen ZZ, Liu TJ, Agarwal G,
Tajima T, Paik NS, Sandelin K, Derossis A, Cody H and Foulkes WD:
Is breast cancer the same disease in Asian and Western countries?
World J Surg. 34:2308–2324. 2010. View Article : Google Scholar : PubMed/NCBI
|
4
|
Foulkes WD, Smith IE and Reis-Filho JS:
Triple-negative breast cancer. N Engl J Med. 363:1938–1948. 2010.
View Article : Google Scholar : PubMed/NCBI
|
5
|
Scorilas A, Kyriakopoulou L, Yousef GM,
Ashworth LK, Kwamie A and Diamandis EP: Molecular cloning, physical
mapping, and expression analysis of a novel gene, BCL2L12, encoding
a proline-rich protein with a highly conserved BH2 domain of the
Bcl-2 family. Genomics. 72:217–221. 2001. View Article : Google Scholar : PubMed/NCBI
|
6
|
Hong Y, Yang J, Chi Y, Wang W, Wu W, Yun
X, Kong X and Gu J: BCL2L12A localizes to the cell nucleus and
induces growth inhibition through G2/M arrest in CHO cells. Mol
Cell Biochem. 333:323–330. 2010. View Article : Google Scholar
|
7
|
Hong Y, Yang J, Wu W, Wang W, Kong X, Wang
Y, Yun X, Zong H, Wei Y, Zhang S, et al: Knockdown of BCL2L12 leads
to cisplatin resistance in MDA-MB-231 breast cancer cells. Biochim
Biophys Acta. 1782:649–657. 2008. View Article : Google Scholar : PubMed/NCBI
|
8
|
Thomadaki H, Talieri M and Scorilas A:
Prognostic value of the apoptosis related genes BCL2 and BCL2L12 in
breast cancer. Cancer Lett. 247:48–55. 2007. View Article : Google Scholar
|
9
|
Florou D, Papadopoulos IN and Scorilas A:
Molecular analysis and prognostic impact of the novel apoptotic
gene BCL2L12 in gastric cancer. Biochem Biophys Res Commun.
391:214–218. 2010. View Article : Google Scholar
|
10
|
Stegh AH, Brennan C, Mahoney JA, Forloney
KL, Jenq HT, Luciano JP, Protopopov A, Chin L and Depinho RA:
Glioma oncoprotein Bcl2L12 inhibits the p53 tumor suppressor. Genes
Dev. 24:2194–2204. 2010. View Article : Google Scholar : PubMed/NCBI
|
11
|
Stegh AH, Kesari S, Mahoney JE, Jenq HT,
Forloney KL, Protopopov A, Louis DN, Chin L and DePinho RA:
Bcl2L12-mediated inhibition of effector caspase-3 and caspase-7 via
distinct mechanisms in glioblastoma. Proc Natl Acad Sci USA.
105:10703–10708. 2008. View Article : Google Scholar : PubMed/NCBI
|
12
|
Stegh AH, Chin L, Louis DN and DePinho RA:
What drives intense apoptosis resistance and propensity for
necrosis in glioblastoma? A role for Bcl2L12 as a multifunctional
cell death regulator. Cell Cycle. 7:2833–2839. 2008. View Article : Google Scholar : PubMed/NCBI
|
13
|
Stegh AH, Kim H, Bachoo RM, Forloney KL,
Zhang J, Schulze H, Park K, Hannon GJ, Yuan J, Louis DN, et al:
Bcl2L12 inhibits post-mitochondrial apoptosis signaling in
glioblastoma. Genes Dev. 21:98–111. 2007. View Article : Google Scholar : PubMed/NCBI
|
14
|
Chou CH, Chou AK, Lin CC, Chen WJ, Wei CC,
Yang MC, Hsu CM, Lung FW, Loh JK, Howng SL, et al: GSK3β regulates
Bcl2L12 and Bcl2L12A anti-apoptosis signaling in glioblastoma and
is inhibited by LiCl. Cell Cycle. 11:532–542. 2012. View Article : Google Scholar : PubMed/NCBI
|
15
|
Lee MT, Ho SM, Tarapore P, Chung I and
Leung YK: Estrogen receptor β isoform 5 confers sensitivity of
breast cancer cell lines to chemotherapeutic agent-induced
apoptosis through interaction with Bcl2L12. Neoplasia.
15:1262–1271. 2013. View Article : Google Scholar : PubMed/NCBI
|
16
|
Giulietti A, Overbergh L, Valckx D,
Decallonne B, Bouillon R and Mathieu C: An overview of real-time
quantitative PCR: Applications to quantify cytokine gene
expression. Methods. 25:386–401. 2001. View Article : Google Scholar
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2[−ΔΔC(T)] method. Methods. 25:402–408. 2001. View Article : Google Scholar
|
18
|
Fendri A, Kontos CK, Khabir A,
Mokdad-Gargouri R and Scorilas A: BCL2L12 is a novel biomarker for
the prediction of short-term relapse in nasopharyngeal carcinoma.
Mol Med. 17:163–171. 2011. View Article : Google Scholar :
|
19
|
Talieri M, Diamandis EP, Katsaros N,
Gourgiotis D and Scorilas A: Expression of BCL2L12, a new member of
apoptosis-related genes, in breast tumors. Thromb Haemost.
89:1081–1088. 2003.PubMed/NCBI
|
20
|
Thomadaki H, Talieri M and Scorilas A:
Treatment of MCF-7 cells with taxol and etoposide induces distinct
alterations in the expression of apoptosis-related genes BCL2,
BCL2L12, BAX, CASPASe-9 and FAS. Biol Chem. 387:1081–1086. 2006.
View Article : Google Scholar : PubMed/NCBI
|
21
|
Yang J, Hong Y, Wang W, Wu W, Chi Y, Zong
H, Kong X, Wei Y, Yun X, Cheng C, et al: HSP70 protects BCL2L12 and
BCL2L12A from N-terminal ubiquitination-mediated proteasomal
degradation. FEBS Lett. 583:1409–1414. 2009. View Article : Google Scholar : PubMed/NCBI
|
22
|
Stegh AH, Kesari S, Mahoney JE, Jenq HT,
Forloney KL, Protopopov A, Louis DN, Chin L and DePinho RA:
Bcl2L12-mediated inhibition of effector caspase-3 and caspase-7 via
distinct mechanisms in glioblastoma. Proc Natl Acad Sci USA.
105:10703–10708. 2008. View Article : Google Scholar : PubMed/NCBI
|
23
|
Stegh AH, Chin L, Louis DN and DePinho RA:
What drives intense apoptosis resistance and propensity for
necrosis in glioblastoma? A role for Bcl2L12 as a multifunctional
cell death regulator. Cell Cycle. 7:2833–2839. 2008. View Article : Google Scholar : PubMed/NCBI
|
24
|
Malin D, Strekalova E, Petrovic V, Deal
AM, Al Ahmad A, Adamo B, Miller CR, Ugolkov A, Livasy C, Fritchie
K, et al: α-crystallin: a novel regulator of breast cancer
metastasis to the brain. Clin Cancer Res. 20:56–67. 2014.
View Article : Google Scholar :
|